Of this proinflammatory cytokines, IL-6, IL-17, TNF-α, and IFN-α suppression have been reported as therapeutic targets for clinical management of lupus and other chronic inflammatory diseases (2, 53–55). This evidence concerns the gene IL17A and systemic lupus erythematosus.